Search results for Fibronectin antibody

Fibronectin antibody [568], Genetex, GTX34730

Fibronectin Antibody (YA762), MedChemexpress, HY-P80674

Fibronectin Antibody (YA762) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Fibronectin.

Fibronectin Antibody (YA436), MedChemexpress, HY-P80493

Fibronectin Antibody (YA436) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Fibronectin.

Fibronectin antibody [HL2761], Genetex, GTX639626

Fibronectin antibody [2F4], Genetex, GTX60570

Fibronectin antibody [2F4G2], Genetex, GTX60571

Fibronectin antibody [GT742], Genetex, GTX634808

Anti-Fibronectin antibody, Abcam, AB2413

Anti-Fibronectin antibody (ab2413) is a rabbit polyclonal antibody and is validated for use in ICC/IF, IHC-P, WB in human samples. Anti-Fibronectin antibody (ab2413) has been cited over 977 times in peer reviewed journals and is trusted by the scientific community. Abcam's high quality validation processes ensure Anti-Fibronectin antibody (ab2413) has high sensitivity and specificity. Anti-Fibronectin antibody (ab2413) has 89 independent reviews from customers. Anti-Fibronectin antibody (ab2413) specifically detects Fibronectin (UniProt ID: P02751; Molecular weight: 269kDa) and is sold in 250 µL selling sizes. Fibronectin (FN1) is a glycoprotein that plays a critical role in the extracellular matrix (ECM) and is significantly upregulated in the tumor microenvironment. Fibronectin (FN1) facilitates tumor angiogenesis, providing essential nutrients to the growing tumor. It also aids in cancer cell invasion and metastasis through interactions with integrins and activation of signaling pathways like FAK/MAPK/ERK and Wnt. Additionally, fibronectin is involved in the epithelial-mesenchymal transition (EMT), which enhances the migratory and invasive capabilities of cancer cells.

Anti-Fibronectin antibody, Abcam, AB299

Biotin Anti-Fibronectin antibody, Abcam, AB6584

This antibody is well suited to detect extracellular matrix proteins in normal as well as disease state tissues. Disruption of tissue organization is the hallmark of neoplasia. Malignant lesions can be distinguished from benign by examining the breakdown of basement membranes and loss of 3-dimensional architecture. Malignant cells are presumed to use matrix metalloproteases to degrade barriers created by the extracellular matrix which then allows metastasis to occur. Collagenases, stomelysins and gelatinases can collectively degrade all of the various components of the extracellular matrix, including fibrillar and non-fibrillar collagens and basement membrane glycoproteins.